These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 17075718)

  • 1. Why are mineralocorticoid receptor antagonists cardioprotective?
    Chai W; Danser AH
    Naunyn Schmiedebergs Arch Pharmacol; 2006 Dec; 374(3):153-62. PubMed ID: 17075718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats.
    Nagata K; Obata K; Xu J; Ichihara S; Noda A; Kimata H; Kato T; Izawa H; Murohara T; Yokota M
    Hypertension; 2006 Apr; 47(4):656-64. PubMed ID: 16505208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A; Saruta T; Funder JW
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor and cardiac arrhythmia.
    Gravez B; Tarjus A; Jaisser F
    Clin Exp Pharmacol Physiol; 2013 Dec; 40(12):910-5. PubMed ID: 23888997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic and nongenomic effects of aldosterone in the rat heart: why is spironolactone cardioprotective?
    Chai W; Garrelds IM; Arulmani U; Schoemaker RG; Lamers JM; Danser AH
    Br J Pharmacol; 2005 Jul; 145(5):664-71. PubMed ID: 15834444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of cardiac fibrosis by aldosterone.
    Lijnen P; Petrov V
    J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RALES, EPHESUS and redox.
    Funder JW
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):121-5. PubMed ID: 15860254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cardioprotective effects of mineralocorticoid receptor antagonists.
    van den Berg TN; Rongen GA; Fröhlich GM; Deinum J; Hausenloy DJ; Riksen NP
    Pharmacol Ther; 2014 Apr; 142(1):72-87. PubMed ID: 24275323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone and mineralocorticoid receptors in the cardiovascular system.
    Funder JW
    Prog Cardiovasc Dis; 2010; 52(5):393-400. PubMed ID: 20226957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor activation in myocardial infarction and failure: recent advances.
    Galuppo P; Bauersachs J
    Eur J Clin Invest; 2012 Oct; 42(10):1112-20. PubMed ID: 22536780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroidogenesis vs. steroid uptake in the heart: do corticosteroids mediate effects via cardiac mineralocorticoid receptors?
    Chai W; Hofland J; Jansen PM; Garrelds IM; de Vries R; van den Bogaerdt AJ; Feelders RA; de Jong FH; Danser AH
    J Hypertens; 2010 May; 28(5):1044-53. PubMed ID: 20179635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aldosterone blockade in heart failure.
    Struthers AD
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5 Suppl 1():S23-7. PubMed ID: 15526239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone inhibition and cardiovascular protection: more important than it once appeared.
    Martinez FA
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):345-50. PubMed ID: 20676926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldosterone, mineralocorticoid receptor, and heart failure.
    Messaoudi S; Azibani F; Delcayre C; Jaisser F
    Mol Cell Endocrinol; 2012 Mar; 350(2):266-72. PubMed ID: 21784127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
    Jewell CW; Watson LE; Mock J; Dostal DE
    Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells.
    Jaffe IZ; Mendelsohn ME
    Circ Res; 2005 Apr; 96(6):643-50. PubMed ID: 15718497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone and end-organ damage.
    Marney AM; Brown NJ
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis.
    Young MJ; Rickard AJ
    Mol Cell Endocrinol; 2012 Mar; 350(2):248-55. PubMed ID: 21930186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
    Zannad F; Radauceanu A
    Heart Fail Rev; 2005 Jan; 10(1):71-8. PubMed ID: 15947894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.